Market Place
Sourcing Support
Enanta Starts Phase 1 Trial of Once-Daily EDP-978 in Urticaria
13 Apr 2026 //
PHARMIWEB
Enanta Pharma Shares Zelicapavir RSV Data at ESCMID
07 Apr 2026 //
PHARMIWEB
Enanta To Present STAT6 Inhibitor Data At IMMUNOLOGY 2026
30 Mar 2026 //
BUSINESSWIRE
Enanta Pharma Presents at Citizens Life Sciences Conference
03 Mar 2026 //
BUSINESSWIRE
Enanta Pharma Discloses Q1 Fiscal Results Ended Dec 31, 2025
09 Feb 2026 //
BUSINESSWIRE
Enanta Pharma Updates Research Programs & 2026 Outlook
08 Jan 2026 //
PHARMIWEB
Enanta Pharma Presents at 44th J.P. Morgan Healthcare Conference
05 Jan 2026 //
BUSINESSWIRE
Enanta Pharma Reveals Fiscal Q4 & Full-Year 2025 Financials
17 Nov 2025 //
BUSINESSWIRE
Enanta Pharma To Join Investor Conferences
04 Nov 2025 //
BUSINESSWIRE
Enanta Pharma Unveils Zelicapavir And EDP-323, Data For RSV
20 Oct 2025 //
BUSINESSWIRE
Enanta To Present Zelicapavir, EDP-323 RSV Data At IDWeek 2025
07 Oct 2025 //
PHARMIWEB
Enanta Pharma Closes Oversubscribed Stock Offering
02 Oct 2025 //
BUSINESSWIRE
Enanta Pharma Plans Public Stock Offering
30 Sep 2025 //
BUSINESSWIRE
Enanta Pharma Sets Price For Increased Stock Offering
30 Sep 2025 //
BUSINESSWIRE
Enanta`s RSVTreatment Helps Speed up Recovery in Study
30 Sep 2025 //
REUTERS
Enanta To Share Ph 2b Zelicapavir Results In RSV High-Risk Adults
26 Sep 2025 //
BUSINESSWIRE
Enanta Pharmaceuticals to Join September Investor Conferences
21 Aug 2025 //
BUSINESSWIRE
Enanta Pharmaceuticals in Baird’s Biotech Discovery Series
15 Jul 2025 //
BUSINESSWIRE
Enanta Pharmaceuticals at Jefferies Global Healthcare Conference
27 May 2025 //
BUSINESSWIRE
Enanta Pharmaceuticals to Present Zelicapavir Data at ESPID
22 May 2025 //
BUSINESSWIRE
Enanta Pharmaceuticals Reports Q2 Financial Results Mar 31, 2025
12 May 2025 //
BUSINESSWIRE
Enanta Pharma Reports Financial Results for Fiscal Q1 End Dec 31
10 Feb 2025 //
BUSINESSWIRE
Enanta Pharma to Present at 43rd Annual J.P. Morgan Conference
08 Jan 2025 //
BUSINESSWIRE
Enanta Pharma Reports Positive Ph 2 Results for Zelicapavir in RSV
09 Dec 2024 //
BUSINESSWIRE
Enanta RSV antiviral reduces viral load in ph. 2 pediatric trial
09 Dec 2024 //
FIERCE BIOTECH
Enanta Reports Positive EDP-323 Results In RSV Study
26 Sep 2024 //
BUSINESSWIRE
Enanta Pharmaceuticals to Participate in Investor Conferences in September
03 Sep 2024 //
BUSINESSWIRE
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter
05 Aug 2024 //
BUSINESSWIRE
Enanta makes the case for COVID-19 antiviral`s mixed data
09 May 2023 //
FIERCE BIOTECH
Enanta PharmaPresents Data for its COVID-19 and Respiratory Syncytial Virus
17 Apr 2023 //
BUSINESSWIRE
Enanta Pharmaceuticals to Present Data at the 33rd ECCMID
05 Apr 2023 //
BUSINESSWIRE
